Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE004 (DEU) (Dr. Tanaka)
· consented 2023-02-28
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-21 (study day 10); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Aspartate aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-04-22 (study day 42); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-05-11 (study day 61); relationship: N
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-07-02 (study day 479); relationship: N
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-08-16 (study day 524); relationship: N
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-09-02 (study day 541); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.